Thursday, 21 August 2014

Alemtuzumab gets a license in Chile

Is early, effective, induction therapy the new treatment paradigm for MS? #MSBlog #MSResearch

"As promised the following are my slides from yesterday's talk at the SINS meeting in Santiago, Chile. I was asked to talk on alemtuzumab as it has just been given a license in Chile with the same broad indication as that in Europe. Most of the Chilean MSologists I spoke to have a lot of experience using rituximab off-license so I don't see any problems them using alemtuzumab in their current clinical practice."



CoI: multiple

5 comments:

  1. Hi thanks for posting this. Did Alemtuzumab get licensed in Chile this month?

    ReplyDelete
  2. How does rituximab off-license prepare them for alemtuzumab?
    Rituximab does not cause secondary autoimmunity

    ReplyDelete
    Replies
    1. Re: "How does rituximab off-license prepare them for alemtuzumab?"

      We don't know they have never been compared head-2-head and we don't have phase 3 data on rituximab; only phase 2 data.

      Delete
  3. What is the connection between the Chilean MSologists rituximab experience and future alemtuzumab use

    ReplyDelete
    Replies
    1. Re: "What is the connection between the Chilean MSologists rituximab experience and future alemtuzumab use>"

      Two reasons; (1) the fact that are prepared to use an induction-like agent (irreversible mode of action) to treat MS means they are psychologically prepared to use alemtuzumab; (2) the set-up for giving rituximab is similar to that what is required to use alemtuzumab.

      Delete